Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Cerimon Pharmaceuticals PPD |
---|---|
Information provided by: | Cerimon Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00640705 |
The primary purpose of this study is to assess the effectiveness of once daily application of a diclofenac sodium patch to the skin near or over the painful area. In this study, the location being studied will be either the left or right ankle.
The secondary purpose of this study is to assess the safety and tolerability of a diclofenac patch on the skin.
Condition | Intervention | Phase |
---|---|---|
Ankle Sprain |
Drug: diclofenac sodium Drug: Matching placebo patch |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Diclofenac Sodium Patch for the Topical Treatment of Pain Due to Mild to Moderate Ankle Sprain. |
Enrollment: | 170 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | October 2008 |
Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Active Comparator
Topical diclofenac sodium patch
|
Drug: diclofenac sodium
15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
|
B: Placebo Comparator
Topical patch identical in appearance to active comparator, except without diclofenac sodium
|
Drug: Matching placebo patch
Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
|
Cerimon Pharmaceuticals is investigating a topical patch formulation of diclofenac sodium containing 15 mg of diclofenac sodium for the local treatment of acute musculoskeletal pain.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Cerimon Pharmaceuticals, Inc. ( Dan Levitt, MD ) |
Study ID Numbers: | DCF-002 |
Study First Received: | March 18, 2008 |
Last Updated: | September 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00640705 History of Changes |
Health Authority: | United States: Institutional Review Board; United States: Food and Drug Administration |
Anti-Inflammatory Agents Analgesics, Non-Narcotic Cyclooxygenase Inhibitors Wounds and Injuries Diclofenac Disorders of Environmental Origin |
Anti-Inflammatory Agents, Non-Steroidal Pain Peripheral Nervous System Agents Analgesics Antirheumatic Agents Sprains and Strains |
Anti-Inflammatory Agents Molecular Mechanisms of Pharmacological Action Cyclooxygenase Inhibitors Physiological Effects of Drugs Wounds and Injuries Disorders of Environmental Origin Diclofenac Enzyme Inhibitors Pharmacologic Actions |
Analgesics, Non-Narcotic Sensory System Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents Sprains and Strains |